Free Trial

HLS Therapeutics (TSE:HLS) Stock Price Down 4.3% - Time to Sell?

HLS Therapeutics logo with Medical background

HLS Therapeutics Inc. (TSE:HLS - Get Free Report) fell 4.3% on Wednesday . The stock traded as low as C$3.76 and last traded at C$3.77. 1,592 shares changed hands during trading, a decline of 93% from the average session volume of 24,348 shares. The stock had previously closed at C$3.94.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus decreased their price target on HLS Therapeutics from C$3.75 to C$3.25 in a research note on Tuesday, August 13th.

View Our Latest Stock Analysis on HLS

HLS Therapeutics Trading Down 1.9 %

The company has a market capitalization of C$117.62 million, a price-to-earnings ratio of -3.66 and a beta of 1.07. The company has a current ratio of 2.02, a quick ratio of 1.01 and a debt-to-equity ratio of 100.44. The business's 50 day moving average price is C$3.34 and its two-hundred day moving average price is C$3.72.

HLS Therapeutics (TSE:HLS - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported C($0.25) earnings per share for the quarter, meeting analysts' consensus estimates of C($0.25). The firm had revenue of C$19.87 million for the quarter, compared to analyst estimates of C$19.25 million. HLS Therapeutics had a negative net margin of 40.90% and a negative return on equity of 24.82%. On average, equities analysts predict that HLS Therapeutics Inc. will post -0.12 earnings per share for the current fiscal year.

HLS Therapeutics Company Profile

(Get Free Report)

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.

See Also

→ Let’s be blunt (From DTI) (Ad)

Should you invest $1,000 in HLS Therapeutics right now?

Before you consider HLS Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HLS Therapeutics wasn't on the list.

While HLS Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines